Lilly teams up with Regor to develop drugs for metabolic disorders
Lilly will make an upfront payment of up to $50m to Regor, in addition to potential milestone payments…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
13 Dec 21
Lilly will make an upfront payment of up to $50m to Regor, in addition to potential milestone payments…
10 Dec 21
Last month, the US regulator has expanded the EUA for a booster dose of the vaccine to include…
09 Dec 21
In the Phase 3 trial, a single dose of Evusheld, administered as two intramuscular injections, showed superior efficacy…
09 Dec 21
The acquisition will enable Thermo Fisher to provide a complete suite of discovery, clinical trial logistics, development and…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
08 Dec 21
The vaccine showed 71% overall efficacy against all variants of SARS-COV-2, and 75.6% in people who were not…
08 Dec 21
The transaction will enable Alvotech to further invest in its platform and portfolio, and support its goal of…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
07 Dec 21
Roche said that the data from four clinical studies showed that Actemra/RoActemra reduced the risk of death in…
07 Dec 21
Thermo Fisher will dedicate its manufacturing facility in Ontario, Canada to make Merck’s molnupiravir and distribute the drug…
06 Dec 21
The provisional approval allows children aged five to 11 years to receive the vaccine in two doses, at…
06 Dec 21
The expanded EUA was based on safety and efficacy data of paediatric and infant patients in Phase 2/3…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates